MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/openhrt-2019-001115

Медицинская библиотека · Open heart · 2019

Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation.

Stirrat Colin G, Alam Shirjel, MacGillivray Thomas J, Gray Calum, Dweck Marc Richard, Jones Victor, Wallace William, Payne John R, Prasad Sanjay K, Gardner Roy S, Petrie Mark C, Mirsadraee Saeed, Henriksen Peter, Newby David E, Semple Scott

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Ultra-small superparamagnetic particles of iron oxide (USPIO)-enhanced MRI can detect cellular inflammation within tissues and may help non-invasively identify cardiac transplant rejection. Here, we aimed to determine the normal reference values for USPIO-enhanced MRI in patients with a prior cardiac transplant and examine whether USPIO-enhanced MRI could detect myocardial inflammation in patients with transplant rejection.

METHODS

Ten volunteers and 11 patients with cardiac transplant underwent T2, T2* and late gadolinium enhancement 1.5T MRI, with further T2* imaging at 24 hours after USPIO (ferumoxytol, 4 mg/kg) infusion, at baseline and 3 months.

RESULTS

Ten patients with clinically stable cardiac transplantation were retained for analysis. Myocardial T2 values were higher in patients with cardiac transplant versus healthy volunteers (53.8±5.2 vs 48.6±1.9 ms, respectively; p=0.003). There were no differences in the magnitude of USPIO-induced change in R2* in patients with transplantation (change in R2*, 26.6±7.3 vs 22.0±10.4 s-1 in healthy volunteers; p=0.28). After 3 months, patients with transplantation (n=5) had unaltered T2 values (52.7±2.8 vs 52.12±3.4 ms; p=0.80) and changes in R2* following USPIO (29.42±8.14 vs 25.8±7.8 s-1; p=0.43).

CONCLUSION

Stable patients with cardiac transplantation have increased myocardial T2 values, consistent with resting myocardial oedema or fibrosis. In contrast, USPIO-enhanced MRI is normal and stable over time suggesting the absence of chronic macrophage-driven cellular inflammation. It remains to be determined whether USPIO-enhanced MRI may be able to identify acute cardiac transplant rejection.

TRIAL REGISTRATION NUMBER: NCT02319278349 (https://clinicaltrials.gov/ct2/show/NCT02319278) Registered 03.12.2014 EUDraCT 2013-002336-24.

Для цитирования: Stirrat Colin G, Alam Shirjel, MacGillivray Thomas J, Gray Calum, Dweck Marc Richard, Jones Victor, Wallace William, Payne John R, Prasad Sanjay K, Gardner Roy S, Petrie Mark C, Mirsadraee Saeed, Henriksen Peter, Newby David E, Semple Scott. Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation.. Open heart. 2019. DOI: 10.1136/openhrt-2019-001115.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.